Search Results for “EC” – Page 101 – media

Scientists develop universal donor stem cell therapy to treat degenerative brain diseases in a preclinical study

Scientists at City of Hope have developed universal donor stem cells that could one day provide lifesaving therapy to children with lethal brain conditions, such as Canavan disease, as well as to people with other degenerative diseases, such as Alzheimer’s and multiple sclerosis. The study was recently published in Advanced Science. “The off-the-shelf approach City of Hope is taking can easily be extended to improve the quality of life of cancer patients who are experiencing cognitive impairment or impaired motor function as a side effect of chemotherapy or radiation,” said Yanhong Shi, Ph.D., chair of the Department of Neurodegenerative Diseases and the Herbert Horvitz Professor in Neuroscience at Beckman Research Institute of City of Hope. Shi has been working on this research for 12 years. This is the first time stem cells have been engineered to become universal donors for cell therapy targeting diseases of the central nervous system, Shi ...
- Source: drugdu
- 134
- June 17, 2023
Blue Water Biotech shores up portfolio with purchase of six FDA-approved treatments

Blue Water Biotech has expanded its commercial portfolio with the purchase agreement of six assets from WraSer. The agreement includes an $8.5m cash payment and the offering of one million restricted shares. Blue Water’s deal includes treatments across cardiology, otic infections, and pain management indications and will see Zontivity (vorapaxar), Trezix (acetaminophen-caffeine-dihydrocodeine), Nalfon (fenoprofen calcium), Conjupri (levamlodipine), Otovel (ciprofloxacin and fluocinolone acetonide) and Cetraxal (ciprofloxacin) all exchange hands to Blue Water’s ownership. All six treatments are US Food and Drug Administration (FDA) approved. At market open, shares in Blue Water surged 90% higher than the previous day’s (13 June) market close. The company has a market cap of $20m. Blue Water’s major purchasing agreement comes at a time when pharma mergers and acquisitions are beginning to pick up after a slow start to 2023. Included in the agreement are the patents related to Zontivity – a medication for patients with ...
- Source: drugdu
- 104
- June 17, 2023
Canadian Institutes of Health Research selects Altmetric and Dimensions from Digital Science’s flagship products

Digital Science, a technology company serving stakeholders across the research ecosystem, is pleased to announce that the Canadian Institutes of Health Research (CIHR) has chosen Altmetric and Dimensions from Digital Science’s flagship products to support its belief that research has the power to change lives. CIHR – the Government of Canada’s health research investment agency, which funds world-class research across the country – has signed a single-year deal to utilize Altmetric Explorer for Institutions and Dimensions Analytics (with API), which enables customers to monitor and report on the online activity surrounding research published by an institution, while also benefiting from access to the full Altmetric database. Using Digital Science’s products and tools, CIHR will be able to monitor the online activity surrounding academic research, including the ability to browse by author, group or department for the institution, benchmark against peer organizations, report on the outcomes of outreach activity, and integrate ...
- Source: drugdu
- 107
- June 16, 2023
analysts

Dive Brief Pulsed field ablation (PFA) devices from Boston Scientific, Johnson & Johnson and Medtronic are a threat to Abbott’s $1.9 billion electrophysiology business, according to analysts at Stifel. Abbott is taking a “wait-and-see” approach to PFA, advancing a later generation device in the belief that the first wave of products will have shortcomings that limit adoption, the report said. The analysts see “some logic” to Abbott’s position but expect the company to suffer share losses in the coming years. The pressure could ramp up quickly, with the analysts warning products that make up around 90% of Abbott’s electrophysiology sales could be affected by the switch to PFA by 2025. Dive Insight Abbott has a PFA device in development but it is years behind the front-runners, with first in-human use planned for this year. Based on that, the analysts estimate the device, named Volt, could win approval in the U.S. ...
- Source: drugdu
- 109
- June 15, 2023
Mark Cuban’s Cost Plus Drug Company projects huge savings over Medicare for generic cancer medications

By Neha Mathur Reviewed by Benedette Cuffari, M.Sc. In a recent article published in the Journal of Clinical Oncology, researchers reveal significant cost savings when generic oncology drugs are purchased through the Mark Cuban Cost Plus Drug Company (MCCPDC) as compared to Medicare. Study: Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare. Image Credit: Celil Kirnapci / Shutterstock.com Background There is an urgent need to reduce spending across the system in a dynamic healthcare landscape like that of the United States, which is possible with the equal participation of patients and sponsors. The Medicare program contributes a substantial proportion of prescription drug spending in the U.S., which was already high and continues to increase over time. In fact, in 2019, Medicare and its beneficiaries accounted for 27.2% of the fee-for-service program. Although oncology prescription drugs constituted only 0.6% of overall sales ...
- Source: drugdu
- 92
- June 15, 2023
Biogen Makes Changes to Board of Directors Ahead of Annual Shareholder Meeting

By Tristan Manalac Pictured: A Biogen building/courtesy of PictureDesignSwiss/shutterstock Biogen announced Monday that three of its directors—Alexander Denner, William Jones and Richard Mulligan—will not stand for re-election at the company’s annual stockholder meeting Wednesday. Instead, Susan Langer will be up for election to Biogen’s board of directors. This latest shake-up comes after board chair Stelios Papadopoulos announced he was stepping down from his post after the annual meeting. Papadopoulos will be succeeded by Caroline Dorsa, a long-standing member of Biogen’s board who had previously served for more than two decades at Merck. Meanwhile, Langer is currently serving as president of Souffle Therapeutics, a privately held start-up that has most recently scored $50 million in investments, according to PitchBook. Before that, Langer was also the founding president of Kojin Therapeutics and the founding chief business officer of Paratus Sciences. She also previously worked at Biogen in posts of increasing responsibility. Endpoints ...
- Source: drugdu
- 111
- June 15, 2023
Bayer needs ‘midsize acquisition’ to reach $10B oncology sales goal, exec says

Bayer recently laid out its ambition to achieve $10 billion in sales from its oncology business by 2030 and become a top 10 cancer drug player. To get there, the company is looking outside for a “midsize acquisition,” Bayer’s oncology chief Christine Roth said.Right now, Bayer’s Nubeqa leads the charge in the company’s oncology department, with its sales projected to peak at more than 3 billion euros. In addition, the company’s acquisitions of Vividion Therapeutics, BlueRock Therapeutics and Noria Therapeutics in recent years have bolstered its research capabilities. “We’ve done a lot of activity to fill our early pipeline,” Roth said in an interview with Fierce Pharma on the sidelines of the American Society of Clinical Oncology’s 2023 annual meeting. “But if we want to achieve that top 10 spot in the next four to six years, it’s going to take the right midsize acquisition to get there.” Roth agreed ...
- Source: drugdu
- 114
- June 15, 2023
Millions of patients do not have full recovery of smell or taste senses after COVID infection, study finds

During the COVID-19 pandemic, many patients experienced a loss of taste and smell during and after being infected with SARS-CoV-2. A retrospective study by researchers at Massachusetts Eye and Ear, a member of the Mass General Brigham healthcare system, investigated the loss of olfactory and gustatory senses and estimated that about a quarter of Americans who had COVID-19 reported only partial or no recovery of taste or smell. The results are published in The Laryngoscope. “We wanted to quantify the national impact of smell disorders resulting from COVID,” said Neil Bhattacharyya, MD, FACS, Professor of Otolaryngology at Mass Eye and Ear. “With this data we can understand, in big numbers, how many people lost their sense of smell or taste due to COVID infection and how many people never fully recovered those senses.” The retrospective study utilizes data from the 2021 National Health Interview Survey (NHIS), a branch of the ...
- Source: drugdu
- 120
- June 14, 2023
BioNTech to defend itself against COVID-19 vaccine injury claim in Germany

Two years after the initial COVID-19 vaccine push swept across the globe, Pfizer’s COVID-19 vaccine partner BioNTech is heading to court in its home country of Germany to defend itself against allegations that its shot caused injuries. This lawsuit comes from a German healthcare worker who seeks at least 150,000 euros ($161,500) in damages for alleged bodily harm, plus compensation for unspecified material damage, Reuters reports. The woman claims she suffered from upper-body pain, swollen extremities, fatigue and a sleeping disorder as a result of taking the Comirnaty vaccine. The plaintiff’s attorneys at the firm Rogert & Ulbrich will challenge the vaccine’s positive risk-benefit profile as assessed by European Union regulators and vaccine assessment agencies, according to the news service. Under German drug laws, drugmakers are only liable for side-effect damages if “medical science” can prove their meds have an incorrect label or cause disproportionate harm relative to their benefits, ...
- Source: drugdu
- 90
- June 14, 2023
Johnson & Johnson inks another Stelara patent settlement, this time with Alvotech and Teva

Another biosimilar product copying Johnson & Johnson’s top-selling drug Stelara may enter the U.S. market without a patent infringement challenge by early 2025 thanks to a new settlement.J&J has signed an agreement granting Alvotech and Teva a license for their proposed Stelara biosimilar, AVT04, in the U.S. The settlement allows the biosimilar makers to launch their version no later than Feb. 21, 2025, the companies said Monday. The new Stelara biosim deal follows another one J&J recently inked with Amgen, which gives the latter a license to launch its copycat no later than Jan. 1, 2025. Like Amgen, Alvotech and Teva haven’t gotten the FDA’s blessing for AVT04. The pair in January said the FDA had accepted its application with a decision targeted for the second half of this year. A verdict for Amgen’s version is expected by the end of the third quarter. Settling those biosimilar entry dates is ...
- Source: drugdu
- 118
- June 14, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.